Polymorphisms in HLA-C and KIR alleles are not associated with HAM/TSP risk in HTLV-1-infected subjects

Imagem de Miniatura
Arquivos
art_ASSONE_Polymorphisms_in_HLAC_and_KIR_alleles_are_not_2018.PDF (176.51 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
BAKKOUR, Sonia
MONTALVO, Leilani
SMID, Jerusa
OLIVEIRA, Augusto Cesar Penalva de
Citação
VIRUS RESEARCH, v.244, Special Issue, p.71-74, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Several genetic polymorphisms may be related to susceptibility or resistance to viral disease outcomes. Immunological or genetic factors may act as major triggers of the immune pathogenesis of HAM/TSP. This study investigated the association of immune related genetic polymorphisms with viral and immunological markers. Methods: 247 HTLV-1-infected volunteers, drawn from a larger group of HTLV-infected subjects followed at the Institute of Infectious Diseases ""Emilio Ribas"" (IIER) for up to 19 years, participated in this study, which ran from June 2011 to July 2016. The subjects were classified according to their neurological status into two groups: Group 1 (160 asymptomatic individuals) and Group 2 (87 HAM/TSP patients). Samples were tested for spontaneous lymphocyte proliferation (LPA) and HTLV-1 proviral load (PVL) and for IFN-lambda 4, HLA-C and KIR genotypes using qPCR. Results: We found associations between LPA (p = 0.0001) with HAM/TSP and confirmed the IFN-lambda 4 polymorphism rs8099917, allele GG, as a protective factor using a recessive model (OR = 3.22, CI = 1.10-9.47). Polymorphisms in HLA-C and KIR alleles were not associated with risk of developing HAM/TSP. Conclusion: We demonstrated that age, LPA and an IFN-lambda 4 polymorphism were associated with progression to HAM/TSP. Understanding HAM/TSP pathogenesis can provide important markers of prognostic value for clinical management, and contribute to the discovery of new therapeutic interventions in the future.
Palavras-chave
Polymorphisms, Interferons, HTLV-1, HLA antigens
URI
https://observatorio.fm.usp.br/handle/OPI/26589
Referências
  1. al Basatena NKS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002270
  2. Araya N, 2011, VIRUSES-BASEL, V3, P1532, DOI 10.3390/v3091532
  3. Ashouri E, 2009, TISSUE ANTIGENS, V74, P62, DOI 10.1111/j.1399-0039.2009.01259.x
  4. Assone T., 2016, VIRUSES, V8
  5. Assone T, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003199
  6. Azimi N, 1999, J IMMUNOL, V163, P4064
  7. Benard G, 1996, AM J TROP MED HYG, V54, P7, DOI 10.4269/ajtmh.1996.54.7
  8. Starling ALB, 2013, ACTA TROP, V125, P75, DOI 10.1016/j.actatropica.2012.09.012
  9. Casseb J. O., 2008, CID, V1
  10. Croda MG, 2008, J NEUROL SCI, V269, P133, DOI 10.1016/j.jns.2008.01.004
  11. Dehee A, 2002, J VIROL METHODS, V102, P37, DOI 10.1016/S0166-0934(01)00445-1
  12. Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0
  13. Fuzii HT, 2014, LIFE SCI, V104, P9, DOI 10.1016/j.lfs.2014.03.025
  14. Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
  15. GESSAIN A, 1985, LANCET, V2, P407
  16. Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
  17. Jeffery KJM, 1999, P NATL ACAD SCI USA, V96, P3848, DOI 10.1073/pnas.96.7.3848
  18. Jeffery KJM, 2000, J IMMUNOL, V165, P7278, DOI 10.4049/jimmunol.165.12.7278
  19. Koehler RN, 2009, TISSUE ANTIGENS, V74, P73, DOI 10.1111/j.1399-0039.2009.01265.x
  20. Martins M, 2017, J NEUROVIROL, V23, P125, DOI 10.1007/s13365-016-0484-x
  21. Melamed A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0221-1
  22. Montanheiro PA, 2009, SCAND J IMMUNOL, V70, P403, DOI 10.1111/j.1365-3083.2009.02291.x
  23. Montanheiro P, 2007, J NEUROIMMUNOL, V188, P138, DOI 10.1016/j.jneuroim.2007.05.015
  24. Montanheito PA, 2005, BRAZ J MED BIOL RES, V38, P1643, DOI 10.1590/S0100-879X2005001100011
  25. Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038/sj.leu.2402777
  26. Mozhgani SH, 2017, J MED VIROL, V89, P1102, DOI 10.1002/jmv.24721
  27. Norris PJ, 2010, VIRULENCE, V1, P19, DOI 10.4161/viru.1.1.9868
  28. O'Connor GM, 2012, HUM IMMUNOL, V73, P783, DOI 10.1016/j.humimm.2012.05.006
  29. OSAME M, 1986, LANCET, V1, P1031
  30. POPOVIC M, 1984, SCIENCE, V226, P459, DOI 10.1126/science.6093248
  31. Grassi MFR, 2011, J MED VIROL, V83, P1269, DOI 10.1002/jmv.22087
  32. Saito M., 2012, LEUK RES TREAT, V2012
  33. Sanabani SS, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-374
  34. Scherzer TM, 2011, J HEPATOL, V54, P866, DOI 10.1016/j.jhep.2010.08.024
  35. Talledo M, 2010, J MED VIROL, V82, P460, DOI 10.1002/jmv.21675
  36. Thio CL, 2010, GASTROENTEROLOGY, V138, P1240, DOI 10.1053/j.gastro.2010.02.033
  37. Trevino A, 2012, CLIN INFECT DIS, V55, pE1, DOI 10.1093/cid/cis343
  38. USUKU K, 1988, ANN NEUROL, V23, pS143, DOI 10.1002/ana.410230733
  39. Vineretsky KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103710
  40. Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88

Coleções
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/38
Artigos e Materiais de Revistas Científicas - LIM/40
Artigos e Materiais de Revistas Científicas - LIM/56